Advertisement
LLY vs PFE
Which Stock Would AI Choose? Eli Lilly (LLY) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- LLY is delivering exceptional top-line growth — revenue rose 56% in Q1 2026 and 48% in Q2 2026 — driven by its Mounjaro and Zepbound franchise.
- PFE is a cash-generative, dividend-paying value name trading near 9 times forward earnings, but it faces a near-term patent cliff.
- LLY carries a premium growth valuation (roughly 27 times forward earnings), while PFE trades at a discount that reflects expected near-term earnings declines.
- PFE offers a roughly 6% forward dividend yield, whereas LLY's appeal is almost entirely capital-appreciation driven.
- The two stocks represent contrasting positioning: a high-momentum growth leader versus a defensive, income-oriented reset story.
Introduction
Eli Lilly and Pfizer are two of the largest names in global pharmaceuticals, yet they sit at opposite ends of the investment spectrum. This stock comparison is relevant for traders and investors weighing high-growth momentum against defensive value and income. LLY is the sector's flagship growth story, powered by explosive demand for its GLP-1 (glucagon-like peptide-1) diabetes and obesity medicines, while PFE is navigating fading COVID-19 revenue and upcoming patent expirations even as it rebuilds its pipeline. Understanding their relative performance, growth drivers, and market positioning can help clarify which profile better suits a given portfolio objective.
LLY Overview and Recent Performance
LLY (Eli Lilly and Company) is an Indianapolis-based pharmaceutical leader whose recent performance has been defined by its cardiometabolic franchise. Mounjaro (for type 2 diabetes) and Zepbound (for obesity) generated a combined $14.9 billion in the second quarter of 2026, roughly two-thirds of company revenue, and management has repeatedly raised its full-year guidance — most recently to a range of $85 billion to $87 billion in revenue. Recent market activity has also been shaped by the U.S. launch of Foundayo (orforglipron), the first oral GLP-1 pill approved for weight loss, plus encouraging Phase 3 data for the next-generation candidate retatrutide. Shares have climbed roughly 38% over the trailing 12 months, though momentum has cooled in recent weeks as investors weigh a premium valuation and rising competition, particularly in the oral obesity segment. Sentiment remains constructive, but the stock's rich multiple means expectations are high.
PFE Overview and Recent Performance
PFE (Pfizer Inc.) is a diversified New York–based drugmaker whose recent performance reflects a transition rather than a breakout. Full-year 2026 revenue guidance sits at $60.5 billion to $62.5 billion, and the company has been reshaping its cost base — removing about $7.2 billion over three years, with additional savings announced. Recent market activity has been driven by progress in oncology, where Padcev and Lorbrena are growing strongly, alongside setbacks such as a failed Phase 3 lung-cancer trial that triggered a multibillion-dollar write-down. Declining COVID-19 product revenue and upcoming patent expirations for Eliquis (expected around 2028) and Ibrance (2027) remain central headwinds. Shares have risen roughly 10% year to date and carry a forward dividend yield near 6%, reflecting a value-oriented profile supported by steady cash generation rather than rapid growth.
Trending AI Robots
Tickeron maintains hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and set of covered securities. Because no single bot fits every market regime, only the most suitable strategies for current conditions earn a place in the curated Trending AI Robots section. This shortlist lets traders compare bots by key statistics and performance metrics, ranging from conservative, lower-frequency models to more aggressive intraday strategies. Whether you are evaluating a high-momentum name like LLY or a value-oriented name like PFE, reviewing these AI-driven tools can add a quantitative layer to your own research. Explore the Trending AI Robots page to see which strategies are currently leading.
Head-to-Head Comparison
The clearest contrast between these two names is growth versus value. LLY's business model is concentrated around blockbuster incretin (metabolic hormone) medicines, giving it exceptional momentum but also concentration risk and sensitivity to pricing pressure. PFE's model is far more diversified across oncology, vaccines, primary care, and specialty medicine, yet that breadth exposes it to multiple patent expirations over the next few years. On market sentiment, LLY benefits from a dominant position in the fastest-growing therapeutic category in the industry, while PFE is working to convince investors its pipeline can offset lost exclusivity. Risk factors also diverge: LLY faces competition from Novo Nordisk and emerging biotechs and must sustain volume growth to offset falling realized prices; PFE faces generic erosion of top products and a still-muted COVID-19 franchise. Valuation reflects these trade-offs — LLY trades at a large premium to the market, while PFE trades at a single-digit forward multiple with a substantial dividend.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor LLY for trend-oriented strategies, given its consistent revenue momentum, strong relative performance, and a steady stream of positive catalysts such as new product approvals and pipeline data. The stock's established uptrend and sustained demand growth present a cleaner trend profile. PFE, by contrast, offers stability, income, and value characteristics that may appeal to defensive or dividend-focused models, but its near-term earnings trajectory is less clearly positive. A probabilistic assessment therefore tilts toward LLY for momentum and consistency, while recognizing that PFE's lower valuation and yield could make it more suitable for risk-averse or income-oriented approaches.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LLY is a Buy and PFE is a Hold.
LLY | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 51 Fair valued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 10 | 100 | |
SMR RATING 1..100 | 14 | 83 | |
PRICE GROWTH RATING 1..100 | 41 | 32 | |
P/E GROWTH RATING 1..100 | 58 | 5 | |
SEASONALITY SCORE 1..100 | 29 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (20) in the Pharmaceuticals Major industry is in the same range as LLY (51). This means that PFE’s stock grew similarly to LLY’s over the last 12 months.
LLY's Profit vs Risk Rating (10) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that LLY’s stock grew significantly faster than PFE’s over the last 12 months.
LLY's SMR Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (83). This means that LLY’s stock grew significantly faster than PFE’s over the last 12 months.
PFE's Price Growth Rating (32) in the Pharmaceuticals Major industry is in the same range as LLY (41). This means that PFE’s stock grew similarly to LLY’s over the last 12 months.
PFE's P/E Growth Rating (5) in the Pharmaceuticals Major industry is somewhat better than the same rating for LLY (58). This means that PFE’s stock grew somewhat faster than LLY’s over the last 12 months.
| LLY | PFE | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 78% | 4 days ago 39% |
| Stochastic ODDS (%) | 4 days ago 75% | 4 days ago 52% |
| Momentum ODDS (%) | 4 days ago 66% | 4 days ago 59% |
| MACD ODDS (%) | 4 days ago 67% | 4 days ago 58% |
| TrendWeek ODDS (%) | 4 days ago 69% | 4 days ago 54% |
| TrendMonth ODDS (%) | 4 days ago 69% | 4 days ago 49% |
| Advances ODDS (%) | 6 days ago 70% | 6 days ago 54% |
| Declines ODDS (%) | 11 days ago 55% | 8 days ago 56% |
| BollingerBands ODDS (%) | N/A | 4 days ago 50% |
| Aroon ODDS (%) | 4 days ago 73% | 4 days ago 58% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LLY’s FA Score shows that 2 FA rating(s) are green while PFE’s FA Score has 3 green FA rating(s).
- LLY’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LLY’s TA Score shows that 6 TA indicator(s) are bullish while PFE’s TA Score has 2 bullish TA indicator(s).
- LLY’s TA Score: 6 bullish, 3 bearish.
- PFE’s TA Score: 2 bullish, 6 bearish.
Price Growth
LLY (@Pharmaceuticals: Major) experienced а +3.19% price change this week, while PFE (@Pharmaceuticals: Major) price change was +1.73% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.53%. For the same industry, the average monthly price growth was -5.20%, and the average quarterly price growth was +5.33%.
Reported Earning Dates
LLY is expected to report earnings on Oct 29, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-2.53% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
LLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with JNJ. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then JNJ could also see price increases.